Novo Nordisk(US:NVO) 智通财经网·2025-09-10 07:14Core Viewpoint - Novo Nordisk (NVO.US) plans to cut 9,000 jobs, representing 11.5% of its workforce, to save approximately $1.3 billion annually amid increasing competition from Eli Lilly (LLY.US) [1][2] Group 1: Company Restructuring - The restructuring aims to simplify the company's structure, enhance decision-making speed, and reallocate resources to growth opportunities [1] - The company will incur a one-time restructuring cost of 9 billion Danish kroner in Q3, including asset impairment costs, but expects to save 1 billion kroner in Q4 and 8 billion kroner annually thereafter [1][2] Group 2: Market Challenges - Novo Nordisk is facing declining market share for its weight loss drug Wegovy and diabetes treatment Ozempic, particularly in the U.S., leading to slowed sales growth [1] - The company has implemented a hiring freeze for non-critical positions globally prior to the layoffs [2] Group 3: Financial Outlook - The projected growth in operating profit for the year has been revised down to 4% to 10%, from a previous estimate of 10% to 16%, primarily due to restructuring costs [2] - The company's stock price has dropped nearly 46% since the beginning of the year, with its market capitalization falling to approximately $181 billion from a peak of about $650 billion last year [2]